Litigation over generic competition to opioid capsule Zohydro between Pernix Therapeutics LLC and Alvogen Malta Operations Ltd. will press on after each company failed to nix it.
Patents at issue in the case properly cover eligible subject matter, but it’s premature to say whether they are valid and whether Alvogen’s proposed generic version of Zohydro would infringe them, the U.S. District Court for the District of Delaware ruled May 15. Zohydro (hydrocodone bitartrate) is an extended-release opioid capsule for chronic pain.
Zohydro is a core product for Pernix, based in Morristown, N.J., and the company has fought to protect it ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.